CA2903845C - Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction - Google Patents

Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction Download PDF

Info

Publication number
CA2903845C
CA2903845C CA2903845A CA2903845A CA2903845C CA 2903845 C CA2903845 C CA 2903845C CA 2903845 A CA2903845 A CA 2903845A CA 2903845 A CA2903845 A CA 2903845A CA 2903845 C CA2903845 C CA 2903845C
Authority
CA
Canada
Prior art keywords
selenium
present application
subject
expression
enriched yeast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2903845A
Other languages
English (en)
French (fr)
Other versions
CA2903845A1 (en
Inventor
Ronan Power
Casey EGAN
Alexander YIANNIKOURIS
Zi-Jian LAN
Rijin XIAO
Lewis Collen Jackson
Stefan Kwiatkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alltech Corp
Original Assignee
Alltech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Corp filed Critical Alltech Corp
Publication of CA2903845A1 publication Critical patent/CA2903845A1/en
Application granted granted Critical
Publication of CA2903845C publication Critical patent/CA2903845C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2903845A 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction Active CA2903845C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361788133P 2013-03-15 2013-03-15
US61/788,133 2013-03-15
PCT/US2014/029328 WO2014144776A1 (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Publications (2)

Publication Number Publication Date
CA2903845A1 CA2903845A1 (en) 2014-09-18
CA2903845C true CA2903845C (en) 2022-08-23

Family

ID=51537786

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2903845A Active CA2903845C (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Country Status (15)

Country Link
US (1) US9833486B2 (OSRAM)
EP (1) EP2968404A4 (OSRAM)
JP (1) JP6313418B2 (OSRAM)
KR (1) KR102245702B1 (OSRAM)
CN (3) CN105377271A (OSRAM)
AU (1) AU2014228785B2 (OSRAM)
BR (1) BR112015022514A2 (OSRAM)
CA (1) CA2903845C (OSRAM)
CL (1) CL2015002677A1 (OSRAM)
HK (1) HK1216506A1 (OSRAM)
MX (1) MX359626B (OSRAM)
RU (1) RU2663127C2 (OSRAM)
SG (2) SG10202101918RA (OSRAM)
WO (1) WO2014144776A1 (OSRAM)
ZA (1) ZA201506759B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164143B (zh) 2013-03-14 2019-02-19 杰罗米.J.申塔格 用于将分子引入到乳糜微粒中的胆固醇体囊泡
KR102448455B1 (ko) * 2014-03-14 2022-09-28 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
CA2981138A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
AU2017234662A1 (en) * 2016-03-14 2018-10-04 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
CN110545822A (zh) 2017-05-19 2019-12-06 全技术公司 药剂、组合物及其相关方法
ES3015109T3 (en) * 2018-04-25 2025-04-29 Oncocross Co Ltd Dimenhydrinate and calcium pantothenate for preventing and treating muscular disease
CN108283711A (zh) * 2018-05-06 2018-07-17 冷立娟 一种治疗酒精性心肌病的中药冲剂及其制备方法
CN109820933A (zh) * 2019-02-27 2019-05-31 北京曲佳科技有限公司 减肥片及其制备方法
CN111493325A (zh) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 植物硒肽在制备改善肥胖及代谢综合征组合物中的应用
CN115917310A (zh) * 2020-06-29 2023-04-04 百时美施贵宝公司 用于分析来自生物反应器的样品的自动化系统和方法
CN112129864B (zh) * 2020-09-24 2022-04-01 江南大学 一种富硒植物干粉中硒形态测定的方法
KR102328808B1 (ko) * 2020-12-02 2021-11-22 동의대학교 산학협력단 맥주효모를 이용한 근감소증 예방 및 개선용 조성물
CN114053298A (zh) * 2021-11-19 2022-02-18 华中农业大学 一种用于抑制心肌肥大的药物及模型的构建方法
CN114235989A (zh) * 2021-11-27 2022-03-25 山东省烟台市农业科学研究院 一种测定福美甲胂含量的高效液相色谱法
CN114031650B (zh) * 2021-11-29 2023-05-02 上海交通大学 壳寡糖硒配位化合物及其制备方法和应用
CN114924001B (zh) * 2022-05-12 2024-11-19 中国计量科学研究院 一种基于独立校准的含磷或含硒化合物标准溶液定值方法
CN114931569B (zh) * 2022-06-22 2023-05-16 中国农业科学院油料作物研究所 甲基硒代半胱氨酸在制备提高雄性生殖能力的产品中的应用
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896024A (ja) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル 白金毒解毒剤
BRPI0410962A (pt) * 2003-06-04 2006-07-04 Willem Jacob Serfontein composição de suplementação de nutrientes ou combinação de composições, e, uso de uma composição ou combinação de composições e de uma composição de nutrientes ou combinação de composições
PL214402B1 (pl) 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
TWI319708B (en) * 2005-10-14 2010-01-21 Methods and compositions for altering cell fuction
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2008144543A2 (en) * 2007-05-18 2008-11-27 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy
CA2694928A1 (en) * 2007-07-31 2009-02-05 Board Of Regents, The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
US8796241B2 (en) * 2007-08-29 2014-08-05 Adam Lubin Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase
JP5318108B2 (ja) * 2007-10-16 2013-10-16 アクチゲノミクス エス エイ 脂質代謝を制御するための組成物
CN101579355B (zh) * 2009-05-27 2010-12-08 徐建兴 一种维护线粒体功能的营养组合物及其应用
EP2490711A4 (en) * 2009-10-22 2013-04-03 Propanc Pty Ltd PHARMACEUTICAL COMPOSITION FOR CREATING TREATMENT WITH TRYPSINOGENES AND / OR CHYMOTRYPINOGENS AND AN ACTIVE COMPOUNDS SELECTED FROM A SELENIC COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIDE DEDICATOR
WO2011132799A1 (en) * 2010-04-22 2011-10-27 Kyoto University Method for inducing differentiation of pluripotent stem cells into skeletal muscle or skeletal muscle progenitor cells
KR20120048205A (ko) * 2010-11-05 2012-05-15 한국식품연구원 메틸셀레노시스테인을 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 조성물
EP2705844B1 (en) 2011-04-13 2019-05-22 Ajinomoto Co., Inc. Nutritional composition

Also Published As

Publication number Publication date
KR102245702B1 (ko) 2021-04-28
MX2015013275A (es) 2015-12-11
CN114984038A (zh) 2022-09-02
SG11201507061XA (en) 2015-10-29
AU2014228785A1 (en) 2015-09-24
RU2015139742A (ru) 2017-04-21
SG10202101918RA (en) 2021-03-30
EP2968404A1 (en) 2016-01-20
HK1216506A1 (zh) 2016-11-18
ZA201506759B (en) 2017-03-29
US20160113977A1 (en) 2016-04-28
JP2016516058A (ja) 2016-06-02
CN114533753A (zh) 2022-05-27
CN105377271A (zh) 2016-03-02
MX359626B (es) 2018-10-01
NZ711842A (en) 2021-04-30
WO2014144776A1 (en) 2014-09-18
CA2903845A1 (en) 2014-09-18
AU2014228785B2 (en) 2018-01-25
RU2663127C2 (ru) 2018-08-01
KR20150132374A (ko) 2015-11-25
JP6313418B2 (ja) 2018-04-18
EP2968404A4 (en) 2017-01-04
CL2015002677A1 (es) 2016-12-09
US9833486B2 (en) 2017-12-05
BR112015022514A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
CA2903845C (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
Li et al. Syringaresinol protects against type 1 diabetic cardiomyopathy by alleviating inflammation responses, cardiac fibrosis, and oxidative stress
Huang et al. Honokiol antagonizes doxorubicin-induced cardiomyocyte senescence by inhibiting TXNIP-mediated NLRP3 inflammasome activation
AU2010247734A1 (en) Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
Yang et al. Favourable effects of grape seed extract on intestinal epithelial differentiation and barrier function in IL10-deficient mice
Wang et al. Nitration-mediated deficiency of cystathionine β-synthase activity accelerates the progression of hyperhomocysteinemia
JP2017512828A (ja) 有機セレン化合物の組成物およびその使用方法
Zhang et al. Effects and mechanisms of Polygonati Rhizoma polysaccharide on potassium oxonate and hypoxanthine-induced hyperuricemia in mice
De Riccardis et al. Metabolic response to glatiramer acetate therapy in multiple sclerosis patients
Gong et al. Integration of transcriptomics and metabonomics revealed the protective effects of hemp seed oil against methionine–choline-deficient diet-induced non-alcoholic steatohepatitis in mice
Ru et al. Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects
Qi et al. Ginseng-derived GABAFG ameliorates type 2 diabetes mellitus by modulating autophagy-lysosome pathway and gut microbiota
Özsoy et al. Changes in the expression of oxidative phosphorylation complexes in the aging intestinal mucosa
Xu et al. Metformin-mediated intestinal AMPK activation ameliorates PCOS through gut microbiota modulation and metabolic pathways
Ren et al. Astaxanthin slows down skeletal muscle atrophy in H22 tumor-bearing mice during sorafenib treatment by modulating the gut microbiota
Ma et al. Stabilization of hypoxia-inducible factor 1α and regulation of specific gut microbes by EGCG contribute to the alleviation of ileal barrier disorder and obesity
Gu et al. β-Nicotinamide mononucleotide supplementation prolongs the lifespan of prematurely aged mice and protects colon function in ageing mice
NZ711842B2 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
Yang et al. Exploring the anti-ovarian aging mechanism of He's Yangchao formula: Insights from multi-omics analysis in naturally aged mice
Verma et al. Mitigating Chloramphenicol induced liver toxicity by exploring the therapeutic potential of Astaxanthin and Quercetin
Wang et al. Integrated proteomics and metabolomics to clarify the essential beneficial mechanisms of L-theanine in alleviating ISO-induced cardiac damage in mice
US20230000888A1 (en) Nad-precursors and dietary restriction for treating age related medical conditions
Hegde et al. Supplementation of diet with Astaxanthin and DHA prevents gestational and lactational undernourishment-induced metabolic derangements in dams: a metabolomic approach
Zhang et al. The effects of dietary vitamin D3 on lipid metabolism in turbot (Scophthalmus maximus. L)
Yang et al. Comprehensive analysis of yak milk residue peptides for anti-hypoxic functional foods: targeting neuroinflammation and apoptosis in hypoxic mice

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190109

EEER Examination request

Effective date: 20190109